M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease: Implications in future therapy

Author： Fisher Abraham   Pittel Zipora   Haring Rachel   Bar-Ner Nira   Kliger-Spatz Michal   Natan Niva   Egozi Inbal   Sonego Hagar   Marcovitch Itzhak   Brandeis Rachel  

Publisher： Humana Press, Inc

ISSN： 0895-8696

Source： Journal of Molecular Neuroscience, Vol.20, Iss.3, 2003-08, pp. : 349-356

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

M1 Muscarinic Agonists Target Major Hallmarks of Alzheimer's Disease -an Update

By  

Current Alzheimer Research, Vol. 4, Iss. 5, 2007-12 ,pp. : 577-580

Bentham Science Publishers

Access to resources Recommend Favorite

M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimer's Disease

By  

Current Alzheimer Research, Vol. 6, Iss. 2, 2009-04 ,pp. : 112-117

Bentham Science Publishers

Access to resources Recommend Favorite

Reduced High-Affinity Agonist Binding at the M 1 Muscarinic Receptor in Alzheimer's Disease Brain: Differential Sensitivity to Agonists and Divalent Cations

By Ladner C.J.   Lee J.M.  

Experimental Neurology, Vol. 158, Iss. 2, 1999-08 ,pp. : 451-458

Elsevier

Access to resources Recommend Favorite

Current approaches and future directions of gene therapy in Alzheimer's disease

By Stepanichev M.  

Neurochemical Journal, Vol. 5, Iss. 3, 2011-09 ,pp. : 159-168

MAIK Nauka/Interperiodica

Access to resources Recommend Favorite

The Utility of Muscarinic Agonists in the Treatment of Alzheimer's Disease

By Messer Jr. W.S.  

Journal of Molecular Neuroscience, Vol. 19, Iss. 1-2, 2002-10 ,pp. : 187-196

Humana Press, Inc

Access to resources Recommend Favorite